Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Less expensive, more effective pneumonia vaccines are tested in humans

01.04.2020

Developed by researchers at the Butantan Institute (Brazil) and Boston Children's Hospital, part of the Harvard Medical School (USA), the innovation is capable of providing protection against all serotypes of the bacterium Streptococcus pneumoniae.

A novel vaccine against pneumonia that is less expensive and more effective than those currently used in Brazil is being tested in human patients. Developed by researchers at the Butantan Institute (Brazil) and Boston Children's Hospital, part of the Harvard Medical School (USA), the innovation is capable of providing protection against all serotypes of the bacterium Streptococcus pneumoniae.


Bioreactors for bench-scale production (A); bioreactor for pilot-scale production (B).

Credit: Butantan Institute

"We chose a different strategy to activate the immune response. Instead of targeting the polysaccharides present in the bacterial capsule, as currently available vaccines do, we opted for proteins common to all serotypes of the microorganism," said Luciana Cezar de Cerqueira Leite, a researcher in the Butantan Institute's Special Vaccine Development Laboratory.

The initial research was led by Cerqueira Leite and supported by São Paulo Research Foundation - FAPESP. Phase I and II clinical trials were conducted in Africa and coordinated in the US by the Harvard team, with support from the Bill & Melinda Gates Foundation and the Program for Appropriate Technologies in Health (PATH), a Seattle-based nonprofit dedicated to developing innovations that save lives and improve health.

"It took more than ten years of research to arrive at this cellular vaccine," Cerqueira Leite said. "First, we investigated proteins that could be used as targets. The idea of developing a cellular vaccine occurred to us on the way. We designed the production process and changed the adjuvant [an agent used in conjunction with the vaccine antigen to augment the host's immune response] as well as the administration pathway. Initially, we set out to produce an intranasally administered vaccine, but then we realized that the product would be more efficient if it was administered by intramuscular injection."

Polyvalent

Some 90 serotypes of S. pneumoniae are estimated to exist worldwide. In addition to pneumonia, the bacterium causes meningitis, otitis and sinusitis, among other diseases. The serotypes are defined on the basis of the combination of polysaccharides present in the microorganisms' capsule. In conventional vaccines, this combination determines the antigen to be introduced into the organism to stimulate antibody production. The vaccine developed by the Butantan Institute triggers an immune response regardless of the bacterial serotype.

"We cultured the bacterium without its capsule in the lab and used a special technique to kill it without disintegrating it. So, the inactivated bacterium can be administered as a vaccine. We also identified immunogenic proteins that are common to all S. pneumoniae serotypes," Cerqueira Leite said.

In a recent article published in the journal Expert Review of Vaccines, Cerqueira Leite and collaborators stressed the importance of developing an affordable pneumonia vaccine that is effective against all S. pneumoniae serotypes.

"In the specific case of pneumonia, insisting on the inclusion of new serotypes in conjugate vaccines only leads to increased complexity and higher production costs, making already expensive vaccines even less affordable for developing countries like Brazil," Cerqueira Leite said.

The pneumococcal vaccines currently available are effective against between ten and 13 serotypes, she added. A nonconjugate version covers 23 serotypes but is used mainly to immunize adults, as it is not effective in children.

"The first generation of conjugate vaccines was effective against the seven most prevalent serotypes in Europe and the US [7-valent]. However, because prevalence varied from one region to another, in Brazil it wasn't able to provide very good coverage, only about 60%," she said.

As time passed, it became possible to combine more strains, and eventually 10-valent and 13-valent vaccines were produced, "but there's a problem with this strategy," Cerqueira Leite said. "When you take specific serotypes out of circulation, other strains [with different serotypes] emerge naturally, and the existing vaccines lose their efficacy. This is known as serotype substitution."

As well as being more comprehensive than current vaccines, the cellular vaccine developed by the Butantan Institute is not vulnerable to the problem of serotype substitution. Pricing is another advantage, according to Cerqueira Leite. "It's hard to say exactly how much the vaccine will cost before it's even been approved and produced, but we estimate about two dollars. The polysaccharide vaccine [13-valent] currently costs the citizen who uses a private clinic about 60 dollars. Public services [administered under the umbrella of SUS, Brazil's national health system] pay 15 dollars," she said.

The price is lower largely because the production process is less complex. "To make the 13-valent vaccine, each of the 13 different serotypes has to be cultured separately and purified to obtain the polysaccharides. Also, because it's a conjugate vaccine, a reaction has to be produced between the polysaccharide and a carrier protein. There are several stages. It's a laborious process with several stages and takes almost two years," she said.

The new vaccine can be produced in approximately two months, according to Cerqueira Leite.

Phase I and II clinical trials have been completed, analyzing safety and toxicity and validating immunogenicity, respectively. "We plan to hold another phase II trial in the US. This is the stage where you compare the type of immune response produced in the populations of different countries," she said.

Phase III clinical trials involve a larger number of people and test the vaccine's effectiveness by comparing an immunized group with a group that receives a placebo. A phase III trial has yet to be scheduled for the new vaccine.

###

About São Paulo Research Foundation (FAPESP)

The São Paulo Research Foundation (FAPESP) is a public institution with the mission of supporting scientific research in all fields of knowledge by awarding scholarships, fellowships and grants to investigators linked with higher education and research institutions in the State of São Paulo, Brazil. FAPESP is aware that the very best research can only be done by working with the best researchers internationally. Therefore, it has established partnerships with funding agencies, higher education, private companies, and research organizations in other countries known for the quality of their research and has been encouraging scientists funded by its grants to further develop their international collaboration. You can learn more about FAPESP at http://www.fapesp.br/en and visit FAPESP news agency at http://www.agencia.fapesp.br/en to keep updated with the latest scientific breakthroughs FAPESP helps achieve through its many programs, awards and research centers. You may also subscribe to FAPESP news agency at http://agencia.fapesp.br/subscribe.

Media Contact

Heloisa Reinert
hreinert@fapesp.br
55-119-663-92552

 @AgenciaFAPESP

http://www.fapesp.br 

Heloisa Reinert | EurekAlert!
Further information:
http://agencia.fapesp.br/32835/
http://dx.doi.org/10.1080/14760584.2020.1711055

Further reports about: bacterium immune response pneumonia polysaccharides proteins vaccines

More articles from Life Sciences:

nachricht X-ray scattering shines light on protein folding
10.07.2020 | The Korea Advanced Institute of Science and Technology (KAIST)

nachricht Surprisingly many peculiar long introns found in brain genes
10.07.2020 | Moscow Institute of Physics and Technology

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The spin state story: Observation of the quantum spin liquid state in novel material

New insight into the spin behavior in an exotic state of matter puts us closer to next-generation spintronic devices

Aside from the deep understanding of the natural world that quantum physics theory offers, scientists worldwide are working tirelessly to bring forth a...

Im Focus: Excitation of robust materials

Kiel physics team observed extremely fast electronic changes in real time in a special material class

In physics, they are currently the subject of intensive research; in electronics, they could enable completely new functions. So-called topological materials...

Im Focus: Electrons in the fast lane

Solar cells based on perovskite compounds could soon make electricity generation from sunlight even more efficient and cheaper. The laboratory efficiency of these perovskite solar cells already exceeds that of the well-known silicon solar cells. An international team led by Stefan Weber from the Max Planck Institute for Polymer Research (MPI-P) in Mainz has found microscopic structures in perovskite crystals that can guide the charge transport in the solar cell. Clever alignment of these "electron highways" could make perovskite solar cells even more powerful.

Solar cells convert sunlight into electricity. During this process, the electrons of the material inside the cell absorb the energy of the light....

Im Focus: The lightest electromagnetic shielding material in the world

Empa researchers have succeeded in applying aerogels to microelectronics: Aerogels based on cellulose nanofibers can effectively shield electromagnetic radiation over a wide frequency range – and they are unrivalled in terms of weight.

Electric motors and electronic devices generate electromagnetic fields that sometimes have to be shielded in order not to affect neighboring electronic...

Im Focus: Gentle wall contact – the right scenario for a fusion power plant

Quasi-continuous power exhaust developed as a wall-friendly method on ASDEX Upgrade

A promising operating mode for the plasma of a future power plant has been developed at the ASDEX Upgrade fusion device at Max Planck Institute for Plasma...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Contact Tracing Apps against COVID-19: German National Academy Leopoldina hosts international virtual panel discussion

07.07.2020 | Event News

International conference QuApps shows status quo of quantum technology

02.07.2020 | Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

 
Latest News

X-ray scattering shines light on protein folding

10.07.2020 | Life Sciences

Looking at linkers helps to join the dots

10.07.2020 | Materials Sciences

Surprisingly many peculiar long introns found in brain genes

10.07.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>